Put private labs' proposed merger under microscope

Questions arise over the future market competitiveness of in vitro diagnostic services, and their effect on healthcare costs and insurance premiums.

Modern medical technologies have made in vitro diagnostic (IVD) tests an integral part of the healthcare infrastructure. With just a small blood or urine sample from a patient, IVD service providers can run a wide array of tests for many chronic diseases, and provide comprehensive reports quickly and effortlessly.

Providers of such tests have been in the headlines following news that the Competition and Consumer Commission of Singapore (CCCS) is inviting the public to give feedback on the two-year commitments proposed by Pathology Asia Holdings (PAH) to address competition concerns in the planned merger of two private clinical laboratories ("Feedback sought on proposed commitments in labs merger", The Straits Times, June 22).

Please or to continue reading the full article. Learn more about ST PREMIUM.

Enjoy unlimited access to ST's best work

  • Exclusive stories and features on multiple devices
  • In-depth analyses and opinion pieces
  • ePaper and award-winning multimedia content
A version of this article appeared in the print edition of The Straits Times on June 28, 2019, with the headline 'Put private labs' proposed merger under microscope'. Print Edition | Subscribe